Proprietary formulations include a range of liquids, capsules, powders, and controlled release tablets utilizing Avicannas self-emulsifying drug delivery systems (SEDDS) technology

The advanced formulations offer enhanced stability, bioavailability and controlled release of cannabinoids including (CBD, THC, CBG, CBN and THCv)

Avicanna intends to utilize the technology in its medical and pharmaceutical products and develop these formulations for treatment of neurological diseases and disorders

TORONTO, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Avicanna Inc. (Avicanna or the Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based pharmaceuticals is pleased to announce that it has filed a provisional patent application in the United States Patent and Trademark Office for a novel oral cannabinoid technology (the Formulation Candidates), which is intended to be commercialized globally for medical and pharmaceutical applications including treatment of various neurological diseases and disorders.

Oral administration of cannabinoids is the most convenient route for non-invasive drug delivery. However, due to the highly lipophilic nature and poor water-solubility of cannabinoids the elementary formulations currently available on the market generally have poor bioavailability and lack consistent drug delivery. Avicannas proprietary compositions have been specifically designed to alter the hydrophobic nature of cannabinoids, resulting in enhanced drug solubility which leads to better absorption and bioavailability either sublingually or orally, thereby increasing efficacy of cannabinoids.

Our novel formulations overcome the current limitations of cannabinoid finished products in the market today and offer enhanced absorption of varying cannabinoid profiles with controlled delivery. We expect this will yield better patient outcomes and clinical results, stated Dr. Frantz Le Devedec, Executive Vice President of Research and Product Development at Avicanna.

Story continues

The patent application entitled "Oral cannabinoid compositions and methods of treating neurological diseases and disorders" claims formulations that have been developed through Avicanna's R&D platform utilizing the companys proprietary self-emulsifying drug delivery systems (SEDDS) technology and include a range of drug delivery formats with varying release and absorption profiles including:

Sustained and controlled release tablets designed for linear release of the drug over time and thereby maximizing pharmacological properties and reducing side effects particular to cannabinoids.

Oral capsules c self-emulsifying cannabinoid technology designed to enhance absorption through a fast and effective dispersion mechanism.

Sublingual tablets designed to provide rapid absorption of cannabinoids through the sublingual membrane to reduce first pass metabolism and provide a solution for acute symptom management and

Water-soluble formulations nano-emulsion technology designed for instant dispersion and dissolution of cannabinoids which can be utilized for convenient titration in drug delivery and beverages.

This patent submission is another example of our drug delivery platforms used to develop industry leading products as we continue to innovate and lead the path with advanced, standardized and evidenced based cannabinoid solutions. We are optimistic about the potential of these formulations across several of our commercial and clinical platforms globally, stated Aras Azadian, Chief Executive Officer of Avicanna.

Avicanna intends to conduct further pre-clinical studies in the coming months in order to formalize this provisional application and will incorporate the technology into its clinical pipeline in 2022. If granted, this patent application will provide Avicanna with protection on the use of the Formulation Candidates for neurological diseases, alone or in combination with other therapies.

About Avicanna

Avicanna is a Canadian commercial-stage biopharmaceutical company established in cannabinoid research, development, and evidence-based products for the global consumer, as well as medical and pharmaceutical market segments. In leading global cannabinoid advancements, Avicanna conducts most of its research in Canada at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, located in the MaRS Discovery District. The company actively collaborates with leading Canadian academic and medical institutions. Avicanna has established an industry-leading scientific platform including advanced R&D and clinical development which has led to the commercialization of over twenty products across four main market segments:

Medical Cannabis & Wellness Products: Marketed under the RHO Phyto brand, or Magisterial Preparations, these medical and wellness products are an advanced line of pharmaceutical-grade cannabis products containing varying ratios of cannabidiol (CBD) and tetrahydrocannabinol (THC). The product portfolio contains a full formulary of products including oral, sublingual, topical, and transdermal deliveries that have controlled dosing, enhanced absorption and stability studies supported by pre-clinical data. The advanced formulary is marketed with consumer, patient and medical community education and training. Avicannas medical and wellness product portfolio also forms the foundation of the Companys pharmaceutical pipeline with the contribution of the formulations that form the basis of the products as well as the data generated from sales and participation of the products in real world evidence studies.

CBD Derma-Cosmetic Products: Marketed under the Pura H&W or Pura Earth brands, these registered, clinically tested, derma-cosmetic products include a portfolio of functional CBD topical products.

Pharmaceutical Pipeline: Leveraging Avicannas scientific platform, vertical integration, and real-world evidence, Avicanna has created a pipeline of patent-pending drug candidates which are indication-specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates provide solutions for unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders. Avicannas first pharmaceutical preparation (Trunerox) is in the drug registration stage in South America.

Cannabis Raw Materials, Seeds, and Bulk Formulations: Marketed under the Aureus brand, the Companys raw material business has successfully completed sales to 11 countries. Aureus offers cannabis dried flower, standardized seeds, full spectrum extracts, and cannabinoid distillates, isolated cannabinoids (CBD, THC, cannabigerol (CBG) and other rare cannabinoids), and bulk formulations derived from hemp and cannabis cultivars through its sustainable, economical, and industrial-scale subsidiaries based in Colombia. The majority of the Aureus products are produced at Santa Marta Golden Hemp S.A.S. (SMGH), the Companys majority-owned subsidiary, which is also Good Agricultural and Collection Practices (GACP) certified and has United States Department of Agriculture (USDA) National Organic Program certification for its hemp cultivar.

SOURCE Avicanna Inc.

Stay Connected

For more information about Avicanna, visit http://www.avicanna.com, contact Ivana Maric by email at info@avicanna.com or follow us on social media on Linkedin, Twitter, Facebook or Instagram.

The Company posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCFXPBGdKSxOUOf_VZoSFSUA.

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, "may", "would", "could", "will", "likely", "expect", "anticipate", "believe", "intend", "plan", "forecast", "project", "estimate", "outlook" and other similar expressions and includes statements with respect to the Companys ability to generate data to support a final patent application, the Companys ability to conduct further research on the Formulation Candidate, the grant of any patent for the Formulation Candidate. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, the availability of licenses, approvals and permits, and the utility and application of certain drugs and products. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company's annual information form dated September 3, 2021 and final short form prospectus dated November 27, 2020, filed with the Canadian securities regulators and available under the Company's profile on SEDAR at http://www.sedar.com. The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

See more here:
Avicanna Files a Patent to Protect its Advanced Oral Cannabinoid Platform and its Applications for Neurological Diseases - Yahoo Finance

Get to know Neurologist and Headache Medicine Specialist, Dr. Kamel Ben-Othmane, who serves patients in Virginia.

(ProNewsReport Editorial):- New York City, New York Nov 6, 2021 (Issuewire.com)Dr. Ben-Othmane is a board-certified neurologist and headache medicine specialist practicing at Riverside Neurology Specialists Newport News in Newport News, Virginia. He can additionally be found at the Riverside Neurology & Sleep Specialists Gloucester in Gloucester, Virginia, and Riverside Neurology Specialists Hampton in Hampton, Virginia. With a keen interest in all facets of neurology, Dr. Ben-Othmane specializes in headache medicine and maintains a deep understanding of the profound impact of headache disorders, including migraines, on his patients life.

Born and raised in Tunisia, Dr. Ben-Othmane attended the Medical School of Tunis/ Facult de Mdecine de Tunis in Tunis, Tunisia, and graduated with a medical degree in 1990. Nearly a decade later, he relocated to the United States, where he completed an internship at Virginia Commonwealth University Health System (1999 1999) and neurology residency at the Institute of Neurology and the Medical College of Virginia in Richmond, Virginia (1999 2002)

Upon the completion of his training, Dr. Ben-Othmane obtained board certification in neurology from the American Board of Psychiatry and Neurology (ABPN). The ABPN is a not-for-profit corporation that was founded in 1934 as a method of identifying qualified specialists in psychiatry and neurology. Furthermore, he is board-certified in headache medicine by the United Council of Neurologic Subspecialties (2004), as well as in CT and MRI through the American Society of Neuroimaging (2008).

Neurology is a branch of medicine dealing with disorders of the nervous system. Neurology deals with the diagnosis and treatment of all categories of conditions and diseases involving the central and peripheral nervous systems, including their coverings, blood vessels, and all effector tissue, such as muscle.

Dr. Ben-Othmane is licensed to practice medicine in the state of Virginia. A member of the American Academy of Neurology and the American Headache Society, Dr. Ben-Othmane has been named a Top Doctor in Hampton Roads Magazine on multiple occasions.

Outside his professional commitments, Dr. Ben-Othmane enjoys spending time with his wife, living near the coast in Virginia, running, and traveling.

Learn more about Dr. Kamel Ben-Othmane:Through his findatopdoc profile, https://www.findatopdoc.com/doctor/2242516-Kamel-Ben-Othmane-Neurologist, or through Riverside Neurology Specialists, https://www.riversideonline.com/find-a-doctor/find-a-doctor-results/kamel-ben-othmane

About FindaTopDoc.comFindaTopDoc is a digital health information company that helps connect patients with local physicians and specialists who accept your insurance. Our goal is to help guide you on your journey towards optimal health by providing you with the know-how to make informed decisions for you and your family.

More:
Kamel Ben-Othmane, MD, a Neurologist and Headache Medicine Specialist with Riverside Neurology Specialists - Pro News Report

Article In Brief

An analysis of data from the National Inpatient Sample on pregnant and postpartum patients with acute ischemic stroke treated with mechanical thrombectomy suggests that endovascular therapy is a safe and efficacious treatment option for pregnant and postpartum people.

Endovascular mechanical thrombectomy (MT), an interventional procedure that removes a large blood clot from an artery or vein, is safe and effective for acute ischemic stroke (AIS) in pregnant and postpartum patients, according to a large population-based analysis published online first in the September 20 issue of Stroke.

After a series of landmark trials published in the New England Journal of Medicine in 2015, endovascular therapy has become a standard of treatment for AIS. However, it has not been evaluated in pregnant and postpartum patients, a group that is at increased risk but often excluded from clinical trials of interventional therapies.

Historically, pregnant patients are systemically excluded from clinical trials, so we felt it was important to report on this important subgroup of AIS patients. In prospective randomized controlled trials, MT has shown strong efficacy for the treatment of AIS with a number needed to treat of 2.6 for improved outcomes, senior study author Fawaz Al-Mufti, MD, associate chair of neurology for research and associate professor of neurology, neurosurgery, and radiology at New York Medical College, told Neurology Today.

Using data from the National Inpatient Sample, a database from the Healthcare Cost and Utilization Project, from 2012 to 2018, the authors analyzed data on pregnant and postpartum patients with AIS treated with MT. They compared them with nonpregnant patients treated with MT, and subsequently with pregnant and postpartum patients who were managed medically.

Compared to nonpregnant AIS patients treated with MT, pregnant patients experienced lower rates of intracranial hemorrhage and lower rate of poor functional outcome at discharge, Dr. Al-Mufti said. Our findings suggest that endovascular therapy is a safe and efficacious treatment option for pregnant and postpartum woman with AIS who are eligible. We hope providers as well as patients and their families can look to large database analyses such as our study to have the confidence to pursue this life-saving and deficit-preventing procedure should it otherwise be indicated.

The paper looked at 52,825 women hospitalized for AIS over a seven-year period, 4,590 of whom were pregnant or postpartum (defined as up to six weeks following childbirth). In this group, 180 women were treated with MT; these women tended to be younger (33 versus 71 mean years, p<0.001) and were more likely to present with extreme acute illness severity compared with the group of 48,055 nonpregnant patients treated with MT.

The study's primary clinical endpoints were functional outcome, all-cause in-hospital mortality, and hospital length of stay. Secondary endpoints included neurological complications specifically relevant to MT treatment for AIS, mainly intracranial hemorrhage and subsequent decompressive hemicraniectomy.

Patients treated with MT had lower rates of both intracranial hemorrhage (11 percent vs 24 percent, p=0.069) and poor functional outcome (50 percent vs 72 percent, p=0.003) at discharge. After adjusting for age, illness severity, and stroke severity, women who were pregnant or postpartum still showed an independently associated lower likelihood of developing intracranial hemorrhage (adjusted odds ratio, 0.26 [95% CI, 0.09-0.70]; p=0.008).

The authors also evaluated complications and outcomes between pregnant and postpartum patients treated with MT and those who were medically managed (4,410 patients). Using propensity score matching, the researchers reported pregnant and postpartum patients treated with thrombectomy had an increased rate (17 percent) of venous thromboembolism compared with medically managed pregnant and postpartum patients (0 percent; p=0.001) but a lower rate of pregnancy-related complications (44 percent vs 64 percent, p=0.034).They found no significant difference in postpartum complications, functional outcome at discharge, or hospital length of stay in these patient groups. No patients in the MT group experienced miscarriage after the procedure.

A major strength of the study, Dr. Al-Mufti said, was the large sample size using national data and, particularly, the number of pregnant and postpartum patients who had undergone MT. Although the retrospective nature of our finding is a limitation of the study that would normally warrant prospective validation, given the rarity of ischemic stroke during pregnancy and the postpartum period, prospective trials evaluating the usage of MT would be challenging.

As a result, he said, large-scale, multicenter investigations such as the present analysis offer meaningful insight into the utilization of these treatment modalities.

Vascular neurologists and neurocritical care experts told Neurology Today that this study was an important contribution to an area of stroke care that is insufficiently studied.

The current guidelines from the American Heart Association recommend consideration of these types of therapies including thrombolysis and endovascular MT during pregnancy if a person has disabling deficits and the benefits outweigh bleeding risks, but they make a slightly equivocal recommendation that it is reasonable to do it and don't really make recommendations about the postpartum period, said Eliza C. Miller, MD, assistant professor of neurology in the division of stroke and cerebrovascular disease at Columbia University Medical Center, who focuses on women's cerebrovascular health and cerebrovascular complications of pregnancy and the postpartum period.

This is mainly because there's really been a lack of data because pregnant and postpartum people have been excluded from all of the prospective trials that have looked at the safety and efficacy of these types of hyperacute stroke therapies.

The current paper presents the largest cohort reported to date of pregnant patients with AIS treated with MT, said Christa O'Hana S. Nobleza, MD, MSCI, medical director of the neurocritical care service at Baptist Memorial Hospital and associate professor in the department of neurology at the University of Tennessee Health Science Center in Memphis.

Before this study, there were only case reports or case series reporting on interventional acute stroke therapy for the pregnant. This study evaluated important factors that possibly limited pregnant patients from undergoing MT, such as potential for hemorrhage and worsening outcomes, and showed that those who underwent thrombectomy did not have higher rates of intracranial hemorrhage or worsened outcomes.

The data found an increased use of thrombectomy since the 2015 thrombectomy clinical trials and also showed that the outcomes from thrombectomy in pregnant women versus thrombectomy in nonpregnant women were similar or betterprobably because of the age difference in these two groups, Victor C. Urrutia, MD, FAHA, associate professor of neurology and director of the Comprehensive Stroke Center at the Johns Hopkins Hospital, said. In addition to the increase in thrombectomy, it shows there's a been a decrease in hemicraniectomy, suggesting that perhaps the benefit of thrombectomy, which is mainly decreasing the size of the stroke, has prevented the need of treatments of large stroke-producing edema in the form of hemicraniectomy.

One key takeaway is the group of women treated with MT didn't have pregnancy-related complications or increased mortalityso all of these things that people worry about did not occur, Dr. Miller said. Another interesting finding, she added, was that pregnant and postpartum patients who had MT were more likely to have venous thromboembolism. This could be explained by the fact that those who get MT are people who had a very large stroke, so you're possibly comparing them with people who had a more minor stroke and might be able to get up and walk more easily, she noted. But it is important for us to remember in general that pregnancy and the postpartum state increase the risk of venous thromboembolism very significantly, so just like with all our stroke patients, we must be hypervigilant about preventing this complication.

Overall, this paper establishes more conclusively that endovascular thrombectomy for acute stroke should be made available for pregnant women who meet the criteria, Dr. Urrutia said. I think the paper might change practice in the sense that those who may have been hesitant for lack of data to consider patients who were pregnant and who were having stroke for treatment might more easily consider it.

Dr. Miller agreed. Yes, there can be a discussion of risk, but I would say in the vast majority of cases, the benefits are going to be so much greater than the risks. I hope that this study helps reassure people that it's okay to offer this therapy that's so life- and function-saving.

The limitation of the analysis, as the study authors and all of the commentators pointed out, is its use of an administrative dataset, which does not allow for more nuanced information about the patients or their long-term outcomes beyond hospital discharge.

Still, Dr. Nobleza said she believes this study provides an important foundation for future potential studies analyzing the effect of acute stroke reperfusion therapies on pregnant patients. Study designs that can incorporate the pregnant patient are needed; however, they are challenging. For now, I believe the information from this study can still be utilized to guide shared decision making regarding acute stroke reperfusion therapy for the pregnant population.

Dr. Urrutia said he would also like to see more specific outcome data in future studies, for example, using measures like the modified Rankin score. I doubt that there would be a randomized clinical trial to test this, so I think the future is probably going to be more pooled individual patient data meta-analyses and those types of studies. With a relatively low frequency eventpregnancy-associated stroke treated with thrombectomy, the difficulty is to be able to get enough cases to also witness the more granular data.

Dr. Miller, however, suggested that the concept of excluding people who are pregnant or postpartum from clinical trials should be revisited. Stroke is a major cause of maternal mortality in the United Statesand even more a cause of severe maternal morbidityso we should be doing everything we can to prevent death and disability in people who are pregnant or postpartum.

While she acknowledged the challenging nature of designing such clinical trials, she pointed out that she conducts a lot of research in collaboration with obstetrician-gynecologists, who are experts in doing clinical trials in pregnant and postpartum people, including interventional and medication trials. There's a whole network for maternal fetal medicine trials, just like we have StrokeNet in stroke, and they do these trials all the time, so it's certainly feasible to enroll pregnant people in clinical trials.

Dr. Miller said it is frustrating to see people who happen to be pregnant or postpartum are not being treated for acute stroke in the same way they would be treated if they weren't pregnant. For example, I sometimes see or have heard about imaging being delayed because people are worried about the radiation risk and they wait for the MRI or they don't do the CT angiogram, but all of these things have been shown to have minimal risk in pregnancy, and the recommendations from both the American College of Obstetricians and Gynecologists and also the American College of Radiology state that, in the case of a life-threatening condition in the mother, these types of imaging studies should not be delayed or withheld. Obviously stroke with a large vessel occlusion is life-threatening and function-threatening, Dr. Miller said.

We should all remember that pregnant women and women in the early postpartum time, which is generally considered to be 6 weeks, are at higher risk of stroke than women of the same age and profile, and that we should address acute onset of neurologic deficits the same way that we would address any other person and consider the treatments that are appropriate depending on the cause of those deficits, Dr. Urrutia said.

Dr. Urrutia is the PI of a national randomized multisite trial called OPTIMISTmain, which is funded by Genentech. Dr. Miller receives research support from the National Institutes of Health, National Institute of Neurological Disorders and Stroke, and the Louis V. Gerstner, Jr. Foundation.

See the original post:
Study Finds Endovascular Thrombectomy Safe and Effective in... : Neurology Today - LWW Journals

The award will presented to Dr. Oyesiku at the Societys 2021 Annual Meeting August 8-11.

Nelson M. Oyesiku, MD, PhD, FACS, Chair Chair of the UNC School of Medicine Department of Neurosurgery, will receive the Distinguished Service Award given by the Society of University Neurosurgeons at their 2021 Annual Meeting in Whitefish, Montana, August 8-11.

Prior to joining the UNC faculty on April 1, 2021, Dr. Oyesiku was Professor of Neurological Surgery and Medicine (Endocrinology) at Emory University, Atlanta, Georgia and the Inaugural Daniel Louis Barrow Chair in Neurosurgery, Vice-Chairman of the Department of Neurological Surgery and Director of the Neurosurgical Residency Program. Dr. Oyesikus clinical expertise is pituitary medicine and surgery. Dr. Oyesiku was co-director of the Emory Pituitary Center and has developed one of the largest practices entirely devoted to the care of patients with pituitary tumors in the country and has performed over 3,700 pituitary tumor operations. Dr. Oyesiku obtained his MD from the University of Ibadan, Nigeria. He obtained an MSc in Occupational Medicine from the University of London, UK and completed a PhD in Neuroscience at Emory University. He completed his Surgery Internship at the University of Connecticut-Hartford Hospital and obtained his neurosurgical training at Emory University, Atlanta. He is board-certified by the American Board of Neurological Surgery. He received an NIH K08 Award and Faculty Development Award from the Robert Wood Johnson Foundation was a recipient of an NIH R01 award and PI of the NIH/NINDS R25 Research Education Program for Residents and Fellows in Neurosurgery. Dr. Oyesiku has served on several NIH Study Sections. Dr. Oyesikus research is focused on the molecular pathogenesis of pituitary adenomas, and tumor receptor imaging and targeting for therapy.

Dr. Oyesiku has served on various state, regional, national and international committees for all the major neurosurgical organizations. He has served on the Board of Directors and as Chairman of the American Board of Neurological Surgery. He was on the ACGME-Residency Review Committee of Neurosurgery. He is a Fellow of the American College of Surgeons and has served on its Board of Governors. Dr. Oyesiku has been President of the Congress of Neurological Surgeons. He has served as Secretary/Treasurer and President of the Georgia Neurosurgical Society, President of the Society of University Neurosurgeons, and Vice-President of the American Academy of Neurological Surgeons. He is President of the International Society of Pituitary Surgeons. He is President-Elect of the World Federation of Neurological Surgeons.

Dr. Oyesiku is Editor-in-Chief of NEUROSURGERY, OPERATIVE NEUROSURGERY and NEUROSURGERY OPEN leading journals in neurosurgery. He is author of over 180 scientific articles and book chapters.

He has been selected by his peers as one of The Best Doctors in America and was selected by the Consumer Research Council of America as one of Americas Top Surgeons. He is named in Marquis Whos Who in America. He is a member of the Honor Medical Society Alpha Omega Alpha. He was awarded the Gentle Giant Award by the Pituitary Network Association for his services to Pituitary Surgery and Medicine. He is on the Medical Advisory Board of the Cushings Support and Research Foundation. He has been visiting professor and invited faculty at several departments of neurosurgery in the United States and abroad.

Read more from the original source:
Oyesiku to Receive Distinguished Service Award from Society of University Neurosurgeons | Newsroom - UNC Health and UNC School of Medicine

This article was originally published here

Neurology. 2021 Jul 29:10.1212/WNL.0000000000012578. doi: 10.1212/WNL.0000000000012578. Online ahead of print.

ABSTRACT

The COVID-19 pandemic caused by the SARS-CoV-2 virus has left many unanswered questions for patients with neurological disorders and the providers caring for them. Elderly and immunocompromised patients are at increased risk for severe symptoms due to COVID-19, and the virus may increase symptoms of underlying neurological illness, particularly for those with significant bulbar and respiratory weakness or other neurologic disability. Emerging SARS-CoV-2 vaccines offer substantial protection from symptomatic infection, but both patients and providers may have concerns regarding theoretical risks of vaccination, including vaccine safety and efficacy in the context of immunotherapy and the potential for precipitating or exacerbating neurological symptoms. In this statement on behalf of the Quality Committee of the AAN we review the current literature, focusing on COVID-19 infection in adults with neurological disease, in order to elucidate risks and benefits of vaccination in these individuals. Based on existing evidence, neurologists should recommend COVID-19 vaccination to their patients. For those patients being treated with immunotherapies, attention should be paid to timing of vaccination with respect to treatment and the potential for an attenuated immune response.

PMID:34326180 | DOI:10.1212/WNL.0000000000012578

See the original post:
COVID-19 and Vaccination in the Setting of Neurologic Disease: An Emerging Issue in Neurology - DocWire News

ROCKAWAY, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) -- electroCore Inc.(Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that full enrollment has been achieved for the TR-VENUS study of non-invasive vagal nerve stimulation (nVNS) for the acute treatment of stroke. TR-VENUS is a double blind, randomized, sham-controlled, multi-center clinical trial, conducted at nine major medical centers across Turkey, supported by the Turkish Neurological Society and partially funded through an unrestricted research grant from electroCore.

Stroke is the second highest cause of death and the third leading cause of disability globally . Ischemic stroke, caused by arterial occlusion, is the most common type of stroke. The effectiveness of current management strategies (e.g. rapid reperfusion with intravenous thrombolysis and endovascular thrombectomy) is dependent on time to treatment. Treating stroke quickly and safely is imperative for maximizing the therapeutic benefits of therapy. electroCores small and portable nVNS device, gammaCore Sapphire, offers the opportunity for administration rapidly after the onset of stroke. The scientific hypothesis supporting the TR-VENUS study is based, in part, on preclinical evidence from studies conducted in the lab of Ilknur Ay at Massachusetts General Hospital, Harvard Medical School suggesting that vagus nerve stimulation (VNS) results in a protective effect against ischemic brain injury1.

The TR-VENUS study recruited a total of 60 subjects with ischemic stroke and eight subjects with hemorrhagic stroke. The primary objective was to assess the safety of nVNS in the setting of acute stroke by examining decreases in arterial blood pressure, severe bradycardia, progression of neurological deficits and death. Feasibility was also assessed by determining the proportion of allocated stimulation doses that could be administered. Secondary efficacy outcomes evaluated neurologic deficits and infarct growth. Top-line data will be reported once available and full results will be published in a peer reviewed medical journal later this year.

The lead investigators of the study, Professors Ethem Murat Arsava and Mehmet Akif Topcuoglu of the Department of Neurology, Hacettepe University in Ankara, Turkey, commented, We are very pleased to have successfully completed enrollment of this Phase 2 trial to assess the safety and feasibility of nVNS for the acute treatment of stroke. We are hopeful that nVNS might be a viable option to improve the treatment of acute stroke.

We congratulate and thank the investigators, patients and families that all supported the successful completion of study enrollment and we look forward to the data readout and what it tells us about nVNS potential as an acute treatment for stroke, saidEric Liebler, Senior Vice President of Neurology at electroCore.

For complete details on the study design please see clintrials.gov: https://clinicaltrials.gov/ct2/show/NCT03733431?term=NCT03733431&draw=2&rank=1

About gammaCoregammaCore(nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patients neck over the vagus nerve, gammaCore stimulates the nerves afferent fibers, which may lead to a reduction of pain in patients.

gammaCore is FDA cleared inthe United Statesfor adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients. gammaCore is CE-marked in theEuropean Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults. In 2019, NICE published an evidence-based Medical Technology Guidance document recommending the use of gammaCore for cluster headache withinNHSEngland.

In the US, the FDA has not cleared gammaCore for the treatment of pneumonia and/or respiratory disorders such as acute respiratory stress disorder associated with COVID-19. Please refer to the gammaCore Instructions for Use for all of the important warnings and precautions before using or prescribing this product.

The United States FDA has authorized use of the gammaCore Sapphire CV device for acute use at home or in a healthcare setting to treat adult patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow, and for whom approved drug therapies are not tolerated or provide insufficient symptom relief as assessed by their healthcare provider, by using non-invasive vagus nerve stimulation (VNS) on either side of the patients neck, available under an emergency access mechanism called an EUA.

gammaCore Sapphire CV has neither been cleared nor approved for acute use at home or in a healthcare setting to treat adult patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow, and for whom approved drug therapies are not tolerated or provide insufficient symptom relief as assessed by their healthcare provider, by using non-invasive Vagus nerve Stimulation (nVNS) on either side of the patients neck during the Coronavirus Disease 2019 (COVID-19) pandemic.

gammaCore Sapphire CV has been authorized for the above emergency use by FDA under an Emergency Use Authorization.

gammaCore Sapphire CV has been authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of medical devices under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked.

Further information is available at:

Authorization Letter:https://www.fda.gov/media/139967/download

Fact Sheet for Healthcare Providers:https://www.fda.gov/media/139968/download

Fact Sheet for Patients:https://www.fda.gov/media/139969/download

Instructions for gammaCore usehttps://www.fda.gov/media/139970/download

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The companys current indications are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.

For more information, visitwww.electrocore.com.

Forward-Looking StatementThis press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects, sales and marketing, and product development plans, future cash flow projections, anticipated costs, its pipeline or potential markets for its technologies, the availability and impact of payer coverage, the potential product use for other indications, the results of TR-VENUS study and the potential use of gammaCore for the acute treatment of stroke, and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCores business, sales and marketing, and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to successfully commercialize gammaCore, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with theSECavailable atwww.sec.gov.

Investors:Hans VitzthumLifeSci Advisors617-430-7578hans@lifesciadvisors.com

or

Media Contact:Jackie DorskyelectroCore973-290-0097

1 Ay I, Nasser R, Simon B, Ay H. Transcutaneous Cervical Vagus Nerve Stimulation Ameliorates Acute Ischemic Injury in Rats. Brain Stimul. 2016 Mar-Apr;9(2):166-73. doi: 10.1016/j.brs.2015.11.008. Epub 2015 Dec 1. PMID: 26723020; PMCID: PMC4789082.

See the original post here:
electroCore Announces Full Enrollment of TR-VENUS study of Non-Invasive Vagal Nerve Stimulation (nVNS) for the Acute Treatment of Stroke - BioSpace

Internet-based intervention that includes daily reminders to complete sleep diaries and wear actiwatch can potentially improve sleep in older adults with mild cognitive impairment (MCI), according to study results published in Alzheimers & Dementia.

Patients with MCI are at increased risk for sleep disturbances, and internet-based interventions may aid in improving sleep in this population. As limited data exist on the role of technology in this population, this study aimed at using an existing internet-delivered cognitive behavioral therapy for insomnia, called Sleep Healthy Using the Internet for Older Adult Sufferers of Insomnia and Sleeplessness (SHUti OASIS). SHUti Oasis collects daily sleep diary data and delivers the automated intervention throughout 9 weeks.

In this ongoing study, researchers collected daily sleep diary data using wrist-worn actigraphs over a 14-day period before the intervention and over a 14-day period after the intervention. SHUTi OASIS sent daily morning emails to remind participants to complete the sleep diary and wear the actiwatch at night.

The study sample included 7 patients (mean age 76.0 years; women, 4) and 4 spouses. All patients with MCI completed 10 sleep diaries over the course of 14 days. Most accessed the SHUTi OASIS program daily and wore the actiwatch between 5 and 14 days.

The automated e-mail reminders and logging into SHUTi OASIS program may be associated with the completion of participants sleep diaries. Inconsistent use of actigraphy at night may be secondary to the early-morning timing of e-mail reminders.

Incorporating technology for subjective and objective sleep data collection in this population is promising, and future work should consider frequency and timing of reminders with multimodal technology use, concluded the study researchers.

Reference

Mattos MK, Barnes L, Davis EM, et al. Preliminary feasibility of technology use in an internet-delivered intervention: Improving sleep in older adults with mild cognitive impairment. Alzheimers Dement. Published online December 7, 2020. doi:10.1002/alz.038831

Read the rest here:
Internet-Based Intervention for Sleep in Adults with Mild Cognitive Impairment - Neurology Advisor

Anesthesia Masks Market: Overview

Read Report Overview - https://www.transparencymarketresearch.com/anesthesia-masks-market.html

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=74771

Key Drivers of Global Anesthesia Masks Market

Request for Analysis of COVID-19 Impact on Anesthesia Masks Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=74771

North America to Hold Major Share of Global Anesthesia Masks Market

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=74771

Pre Book Anesthesia Masks Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=74771&ltype=S

Key Players Operating in Global Market

Major players operating in the global anesthesia masks market are:

Browse More Trending Reports by Transparency Market Research:

Flow Diversion Aneurysm Market: https://www.transparencymarketresearch.com/flow-diversion-aneurysm-market.html

Bacteremia Treatment Market: https://www.transparencymarketresearch.com/bacteremia-treatment-market.html

Whipples Disease Market: https://www.transparencymarketresearch.com/whipples-disease-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

Follow this link:
Anesthesia Masks Market: Rising Prevalence of Chronic Diseases and Neurological Disorders to Drive the Market - BioSpace

Reviewed This Month

Effect of Out-of-Hospital Tranexamic Acid vs. Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury.

Authors: Rowell SE, Meier EN, McKnight B, et al.

Published in: JAMA, 2020 Sep 8; 324(10): 96174. Erratum in: JAMA, 2020 Oct 27; 324(16): 1,683.

Over the last decade, the use of tranexamic acid (TXA) for traumatic hemorrhage control has increased. This was due to the results of a clinical trial, published in 2010, that found early administration of TXA was a cost-effective way to reduce the risk of death in bleeding trauma patients.

Further research has shown that TXA is safe for patients with traumatic brain injury (TBI). In this months Journal Watch, we review a randomized, double-blind multicenter trial designed to examine the efficacy and safety of out-of-hospital administration of tranexamic acid compared to placebo in participants with moderate or severe TBI who were not in shock.

The objective of this trial was to determine whether TXA administered by EMS within two hours of injury improved neurologic outcome. Read that objective carefullyit will be important when putting the results of this trial into context.

Neurologic outcome was measured using the Glasgow Outcome Score-Extended (GOSE). The authors chose to dichotomize this scale into favorable (which included moderate disability or good recovery) and poor (which included severe disability, vegetative state, or death) outcomes.

The authors also examined many secondary outcomes, including 28-day mortality, six-month disability, progression of intracranial hemorrhage, incidence of neurosurgical interventions, hospital-free days, ICU-free days, incidence of seizures, and incidence of thrombotic events, to name a few.

The study was conducted in 12 regions across the U.S. and Canada. It included 39 EMS agencies and 20 trauma centers. To be eligible for enrollment in this trial, patients had to be at least 15 years of age, with moderate or severe blunt or penetrating TBI, a GCS score of 3 to 12, at least one reactive pupil, a systolic blood pressure of at least 90 mm Hg, and an IV in place prior to randomization.

Participants were randomized into one of three treatment groups. The first received a 1-gram IV bolus of TXA by EMS followed by a gram of in-hospital TXA infused over eight hours. The next group received a 2-gram TXA bolus by EMS followed by a placebo infusion. The final group received an IV bolus placebo by EMS and a placebo infusion in the hospital. Study kits that appeared identical were shipped to participating EMS agencies for placement on EMS vehicles in random order. Each vehicle only carried one study kit at a time.

The study was conducted between May 2015 and March 2017 under U.S. regulations for exception from informed consent and the Canadian tricouncil policy statement on ethical conduct in research involving humans.

There were 966 patients included in the analysis. Their average age was 42, and almost three-quarters (74%) were male. The average GCS score was 8. The three study groups were similar when comparing demographics and baseline anatomic and physiologic characteristics as well as injury severity. However, the authors note there were fewer penetrating injuries in the bolus-only group.

The median estimated time from injury to EMS administration of the study drug ranged from 40 to 43 minutes. The median time from EMS administration to the start of the in-hospital infusion ranged from 86 to 96 minutes.

The evaluation of the primary study outcome, favorable or poor neurologic function, revealed no statistically significant difference when comparing TXA to placebo (65% vs. 62%, p=0.16). Therefore, the conclusion of this study was that among patients with moderate or severe TBI, out-of-hospital tranexamic acid administration within two hours of injury did not improve six-month neurologic outcome as measured by the GOSE.

However, as we discuss often in this column, we should not let statistical significance alone guide our judgment of importance. There was a 3% difference in favorable neurologic outcome. While that difference may not be statistically significant, could it be clinically meaningful?

Now, rather than simply read the objective and conclusion of this paper, lets dive a little deeper. As mentioned earlier, the authors also examined several secondary outcomes. When evaluating 28-day mortality, the TXA groups showed a 3% improvement (14% vs. 17%). This result was also not statistically significant, with a p-value of 0.26.

There was also an 8% difference in 28-day mortality when comparing the bolus-only group to the placebo group for those patients with intracranial hemorrhage. This difference was statistically significant (p=0.03). The total number of adverse events was also similar between groups.

Why would the authors report such a cut-and-dried conclusion when there seems to be a trend favoring the use of TXA? Well, the authors indicate in their methods section that the study was specifically designed to evaluate neurologic outcomes at six months. This was specified in the original trial registry on ClinicalTrials.gov. The authors had to stick to the primary outcome that was specified prior to the beginning of trial enrollment for the resulting manuscript.

However, the authors are clear that we should carefully interpret their findings. They state in their discussion that despite no statistically significant difference in the primary outcome in either trial, there were important differences and findings from both trials that warrant consideration and future investigation.

In other words, the results seem to be trending in a favorable direction when EMS administers TXA early. So, rather than to simply conclude from these findings that TXA is not effective in the treatment of TBI, an important next step would be to design studies that specifically evaluate outcomes other than the dichotomous GOSE score at six months.

As with all studies there are limitations here. There were some difficulties in obtaining follow-up data six months after the injury. This is not surprising, given that patients were enrolled prior to giving consent. There was also a low percentage of patients with intracranial hemorrhage enrolled in the study. This may have diluted the treatment differences.

This was a very well done study that will lead to further analysis of TXA administration. It is also a great example of how we should avoid letting a p-value alone guide our judgment of importance.

I hope you have an opportunity to read the manuscript yourself. There are many other interesting results that could not fit into this months Journal Watch. And, as always, I hope to review your study in an upcoming edition soon.

Antonio R. Fernandez, PhD, NRP, FAHA, is a research scientist at ESO and an assistant professor in the department of emergency medicine at the University of North CarolinaChapel Hill. He is on the board of advisors of the Prehospital Care Research Forum at UCLA.

Read this article:
Journal Watch: TXA and Neuro OutcomesMore Than Meets the Eye - EMSWorld

Is it possible to predict who will develop Alzheimers disease simply by looking at writing patterns years before there are symptoms?

According to a new study by IBM researchers, the answer is yes.

And, they and others say that Alzheimers is just the beginning. People with a wide variety of neurological illnesses have distinctive language patterns that, investigators suspect, may serve as early warning signs of their diseases.

For the Alzheimers study, the researchers looked at a group of 80 men and women in their 80s half had Alzheimers and the others did not. But, seven and a half years earlier, all had been cognitively normal.

The men and women were participants in the Framingham Heart Study, a long-running federal research effort that requires regular physical and cognitive tests. As part of it, they took a writing test before any of them had developed Alzheimers that asks subjects to describe a drawing of a boy standing on an unsteady stool and reaching for a cookie jar on a high shelf while a woman, her back to him, is oblivious to an overflowing sink.

The researchers examined the subjects word usage with an artificial intelligence program that looked for subtle differences in language. It identified one group of subjects who were more repetitive in their word usage at that earlier time when all of them were cognitively normal. These subjects also made errors, such as spelling words wrongly or inappropriately capitalizing them, and they used telegraphic language, meaning language that has a simple grammatical structure and is missing subjects and words like the, is and are.

The members of that group turned out to be the people who developed Alzheimers disease.

The A.I. program predicted, with 75 percent accuracy, who would get Alzheimers disease, according to results published recently in The Lancet journal EClinicalMedicine.

We had no prior assumption that word usage would show anything, said Ajay Royyuru, vice president of health care and life sciences research at IBM Thomas J. Watson Research Center in Yorktown Heights, N.Y., where the A.I. analysis was done.

Alzheimers researchers were intrigued, saying that when there are ways to slow or stop the illness a goal that so far remains elusive it will be important to have simple tests that can warn, early on, that without intervention a person will develop the progressive brain disease.

What is going on here is very clever said Dr. Jason Karlawish, an Alzheimers researcher at the University of Pennsylvania. Given a large volume of spoken or written speech, can you tease out a signal?

For years, researchers have analyzed speech and voice changes in people who have symptoms of neurological diseases Alzheimers, ALS, Parkinsons, frontotemporal dementia, bipolar disease and schizophrenia, among others.

But, said Dr. Michael Weiner, who researches Alzheimers disease at the University of California, San Francisco, the IBM report breaks new ground.

This is the first report I have seen that took people who are completely normal and predicted with some accuracy who would have problems years later, he said.

The hope is to extend the Alzheimers work to find subtle changes in language use by people with no obvious symptoms but who will go on to develop other neurological diseases.

Each neurological disease produces unique changes in speech, which probably occur long before the time of diagnosis, said Dr. Murray Grossman, a professor of neurology at the University of Pennsylvania and the director of the universitys frontotemporal dementia center.

He has been studying speech in patients with a behavioral form of frontotemporal dementia, a disorder caused by progressive loss of nerves in the brains frontal lobes. These patients exhibit apathy and declines in judgment, self control and empathy that have proved difficult to objectively quantify.

Speech is different, Dr. Grossman said, because changes can be measured.

Early in the course of that disease, there are changes in the pace of the patients speech, with pauses distributed seemingly at random. Word usage changes, too patients use fewer abstract words.

These alterations are directly linked to changes in the frontotemporal parts of the brain, Dr. Grossman said. And they appear to be universal, not unique to English.

Dr. Adam Boxer, director of the neurosciences clinical research unit at the University of California, San Francisco, is also studying frontotemporal dementia. His tool is a smartphone app. His subjects are healthy people who have inherited a genetic predisposition to develop the disease. His method is to show subjects a picture and ask them to record a description of what they see.

We want to measure very early changes, five to 10 years before they have symptoms, he said.

The nice thing about smartphones, Dr. Boxer added, is that you can do all kinds of things. Researchers can ask people to talk for a minute about something that happened that day, he said, or to repeat sounds like tatatatata.

Dr. Boxer said he and others were focusing on speech because they wanted tests that were noninvasive and inexpensive.

Dr. Cheryl Corcoran, a psychiatrist at Icahn School of Medicine at Mount Sinai in New York, hopes to use speech changes to predict which adolescents and young adults at high risk for schizophrenia may go on to develop the disease.

Drugs to treat schizophrenia may help those who are going to develop the disease, but the challenge is to identify who the patients will be. A quarter of people with occasional symptoms saw them go away, and about a third never progressed to schizophrenia although their occasional symptoms persisted.

Guillermo Cecchi, an IBM researcher who was also involved in the recent Alzheimers research, studied speech in 34 of Dr. Corcorans patients, looking for flight of ideas, meaning the instances when patients were off track when talking and spinning off ideas in different directions. He also looked for poverty of speech, meaning the use of simple syntactic structures and short sentences.

In addition, Dr. Cecchi and his colleagues studied another small group consisting of 96 patients in Los Angeles 59 of whom had occasional delusions. The rest were healthy people and those with schizophrenia. He asked these subjects to retell a story that they had just heard, and he looked for the same telltale speech patterns.

In both groups, the artificial intelligence program could predict, with 85 percent accuracy, which subjects developed schizophrenia three years later.

Its been a lot of small studies finding the same signals, Dr. Corcoran said. At this point, she said, we are not at the point yet where we can tell people if they are at risk or not.

Dr. Cecchi is encouraged, although he realizes the studies are still in their infancy.

For us, it is a priority to do the science correctly and at scale, he said. We should have many more samples. There are more than 60 million psychiatric interviews in the U.S. each year but none of those interviews are using the tools we have.

Here is the original post:
Alzheimers Prediction May Be Found in Writing Tests - The New York Times

This article was originally published here

Nervenarzt. 2021 Jan 18. doi: 10.1007/s00115-020-01058-w. Online ahead of print.

ABSTRACT

Neurological diseases are the most common cause of disability worldwide. In addition to physical limitations, they often lead to cognitive deficits that make active participation in professional and social life difficult. Due to physical and cognitive deficits, it is often difficult for neurological patients to gain access to specialized knowledge or to receive specialized treatment and is associated with greatly increased effort. Neurological diseases account for 11.6% of global disability-adjusted life years (DALYs, a measure for quantifying disease burden) and 16.5% of deaths, and remain the leading cause of DALYs and the second leading cause of death worldwide. Neurorehabilitation encompasses the goal of reintegrating patients with neurological dysfunctions into everyday life. The ongoing situation in the context of the COVID-19 pandemic poses new challenges for the healthcare system. Social distancing and quarantine have deprived many people with neurological disorders of access to routine medical care. The corona pandemic is a catalyst for the widespread use of telemedicine in the field of neurology and neurorehabilitation. Projects such as the Brunei project of the Nordwest Krankenhaus Frankfurt as well as an MS clinic in Canada show that highly specialized medicine and neurorehabilitation can be delivered to remote areas or in the living room of patients or any doctors office. Telemedical, telerehabilitative and teletherapeutic applications offer the opportunity to supplement and optimize existing care structures and with modern technology to make a new and contemporary interpretation of old-fashioned medical and therapeutic home visits.

PMID:33459797 | DOI:10.1007/s00115-020-01058-w

Read the original:
Telerehabilitation: from the virtual world to reality-Medicine in the twenty-first century : Video-assisted treatment in times of COVID-19 - DocWire...

Newswise MAYWOOD, ILLoyola Medicine is providing multidisciplinary care for patients with long-term neurological, cognitive and other symptoms associated with COVID-19.

"While most patients with COVID-19 have mild-to-moderate symptoms and recover at home, a fraction of severe, typically hospitalized patients (approximately 10%, according to an article in the British Medical Journal) are discharged with lingering, life-altering symptoms," said Jos Biller, MD, professor and chair, department of neurology, Loyola University Medical Center and Loyola University Chicago Stritch School of Medicine. Dr. Biller is leading the Loyola Medicine COVID-19 neurology clinic.

Persistent neurological symptoms in patients following acute COVID-19 may include fatigue; brain fog; loss of smell (anosmia); distorted or loss of taste (dysgeusia); headache; vertigo; sleep disturbances; loss of muscle mass and strength (sarcopenia); and neuromuscular aches, cramps and pain (myalgia).

"These 'long-haul' patients may also have neuropsychiatric symptoms, including anxiety, depression and post-traumatic stress disorder," said Dr. Biller. "As a result of their symptoms, many of these individuals are unable to return to work and suffer economic stressors."

For older patients, COVID-19 may increase the risk for or exacerbate cognitive decline and dementia, said Dr. Biller, who co-authored the study, "Correlations between COVID-19 and burden of dementia" in the September 2020 Journal of the Neurological Sciences. "Many patients with dementia decline significantly after contracting COVID-19."

In addition to Dr. Biller, the Loyola COVID-19 neurology clinic includes neurologists Stasia Rouse, MD and Kathy Kujawa, MD, PhD. The clinic will refer patients to other specialists including psychiatrists, neuropsychologists, pulmonologists, cardiologists, gastroenterologists, nephrologists, and nutritionists as needed.

"The long-term symptoms of COVID-19 may be protracted," said Richard K. Freeman, MD, MBA, regional chief clinical officer, Loyola Medicine. "Loyola Medicine is committed to providing comprehensive, exemplary care to these patients."

For more information, please visit loyolamedicine.org or loyolamedicine.org/coronavirus.

###

About Loyola MedicineLoyola Medicine, a member of Trinity Health, is a nationally ranked academic, quaternary care system based in Chicago's western suburbs. The three-hospital system includes Loyola University Medical Center, Gottlieb Memorial Hospital and MacNeal Hospital, as well as convenient locations offering primary care, specialty care and immediate care services from more than 1,800 physicians throughout Cook, Will and DuPage counties. Loyola is a 547-licensed-bed hospital in Maywood that includes the William G. & Mary A. Ryan Center for Heart & Vascular Medicine, the Cardinal Bernardin Cancer Center, a Level 1 trauma center, Illinois's largest burn center, a certified comprehensive stroke center and a childrens hospital. Loyola also trains the next generation of caregivers through its academic affiliation with Loyola University Chicagos Stritch School of Medicine and Marcella Niehoff School of Nursing. Gottlieb is a 247-licensed-bed community hospital in Melrose Park with the newly renovated Judd A. Weinberg Emergency Department, the Loyola Center for Metabolic Surgery and Bariatric Care and the Loyola Cancer Care & Research facility at the Marjorie G. Weinberg Cancer Center. MacNeal is a 374-licensed-bed teaching hospital in Berwyn with advanced medical, surgical and psychiatric services, acute rehabilitation, an inpatient skilled nursing facility and a 68-bed behavioral health program and community clinics. Loyola Medical Group, a team of primary and specialty care physicians, offers care at over 15 Chicago-area locations. For more information, visit loyolamedicine.org. You can also follow Loyola Medicine on LinkedIn, Facebook or Twitter.

About Trinity Health Trinity Health is one of the largest multi-institutional Catholic health care delivery systems in the nation, serving diverse communities that include more than 30 million people across 22 states. Trinity Health includes 92 hospitals, as well as100continuing care locations that include PACE programs, senior living facilities, and home care and hospice services. Its continuing care programs provide nearly 2.5 million visits annually. Based in Livonia, Mich., and with annual operating revenues of$18.8billion and assets of$30.5 billion, the organization returns$1.3billion to its communities annually in the form of charity care and other community benefit programs. Trinity Health employs about123,000colleagues, including6,800employed physicians and clinicians. Committed to those who are poor and underserved in its communities, Trinity Health is known for its focus on the country's aging population. As a single, unified ministry, the organization is the innovator of Senior Emergency Departments, the largest not-for-profit provider of home health care services ranked by number of visits in the nation, as well as the nations leading provider of PACE (Program of All Inclusive Care for the Elderly) based on the number of available programs. For more information, visit trinity-health.org. You can also follow Trinity Health on LinkedIn, Facebook or Twitter.

More here:
Loyola Medicine Opens Neurology Clinic for COVID-19 Patients Living with Long-term Neurological and Cognitive Symptoms - Newswise

NEW YORK, Jan. 26, 2021 /PRNewswire/ --Soterix Medical Inc. (SMI), the global leader in non-invasive stimulation and synergistic brain imaging technologies, announces a new clinical trial of home-based auricular Vagus Nerve Stimulation (taVNS) for individuals who experience post-COVID neuropsychiatric symptoms, like fatigue, headache, or anxiety. The trial involves an innovative, first-of-its kind home-based neuromodulation solution that combines Soterix Medical's unique wearable taVNS platform, with ElectraRx portal for remote stimulation control, and home-based vital sign monitoring.

Emerging studies show COVID can affect patients during two distinct phases of the disease process: the acute stage, characterized by fever, heart or lung problems, and the post-COVID phase, in which neuropsychiatric symptoms, like fatigue, anxiety and depression, can occur.

Researchers have used the term "neuroCOVID" to describe when the second phase is characterized by one or a combination of neuropsychiatric symptoms like vertigo, loss of smell, headaches, fatigue and irritability as well as anxiety and depression. Some studies estimate one in five COVID patients will develop these long-term symptoms.

The study is supported in part by the National Institutes of Health-funded Delaware Clinical and Translational Research Program to address neuroCOVID symptoms in patients. The trial is designed around a unique technology suite that combines precise vagus nerve stimulation with real-time remote-control as well as remote physiological sensing by the clinical team. The trial is based on the established anti-inflammatory response to vagus nerve stimulation.

Mr. Kamran Nazim, Chief Product Manager of Soterix Medical adds, "This study will leverage our unparalleled expertise in developing noninvasive technologies to stimulate the vagus nerve. Soterix Medical has over a decade of experience designing and deploying the more reliable, targeted, and intelligent non-invasive brain stimulation devices. Our proprietary remote-controlled taVNS system is uniquely optimized for this novel indication."

Ms. Claudia Giselle, Soterix Medical's VP Regulatory Affairs, adds "In addition to Soterix Medical's unique wearable vagus nerve stimulation platform, this trial integrates technology for telemedicine support including video and real-time home-based blood pressure, pulse and oxygen saturation levels. The sophistication of this integrated system is a testament to our commitment to provide the most advanced stimulation and integrated monitoring technologies, for the most important medical indications of our time."

CAUTION: Soterix Medical taVNS platform is limited by Federal (or United States) law to investigational use only.

Media Contact: Mariana Shuster Tel: +1-888-990-8327 Email: [emailprotected]

SOURCE Soterix Medical Inc.

Read this article:
Soterix Medical study to address post-COVID neurological and psychiatric symptoms using at-home neuromodulation and monitoring - PRNewswire

Review: Oliver Sacks: His Own Life, directed by Ric Burns

Apropos of nothing but a bowl of jello placed before him, a stifled laugh escapes from Oliver Sacks, the famed neurologist, writer and public intellectual.

What are you thinking about? asks a voice offscreen.

Sacks demurs at first or perhaps feigns reluctance then relents.

Until a few years ago, I would wake up at night with an erection. Nothing to do with sexual excitement But it was at times irritatingly persistent. So, I would sometimes cool my turgid penis in orange jello.

Such vignettes from Oliver Sacks: His Own Life reveal the usually shy, but often cheeky and sometimes shockingly honest character of the late Sacks.

Shortly after receiving a fatal diagnosis in January, 2015, Sacks invited documentarian Ric Burns and crew for a series of interviews in his New York City apartment. Sacks second memoir, On the Move, would be published in April. He passed away just a few months later.

Read more: 'I want to stare death in the eye': why dying inspires so many writers and artists

The film is structured around Sacks reading brief passages from his memoir, accompanied by archival footage of the avuncular physician in action. Also interspersed are pithy recollections from fellow neurologists, writers, editors, patients, family and friends.

Rather than retreading previous thoughts on Sacks style of romantic science, its worth considering what the documentary offers that existing memoirs, biographies and other accounts do not.

Firstly, for those unfamiliar with Sacks, the film provides the most efficient but palatable jello anecdotes aside summary of his life, work and character.

Moreover, it reconciles how Sacks seemingly wild contradictions would (eventually) become complements. A recurring theme is that Sacks was immoderate in all directions, living a life that whiplashed between extremes of hedonism and self-discipline.

Sacks possessed a curious mix of extraordinary erudition, voracious appetite and self-destructive tendencies. This was leavened by seemingly boundless empathy for the neurologically marginalised, for whom he so poetically advocated.

Read more: How Oliver Sacks brought readers into his patients' inner worlds

By all accounts, including those of his partner Bill Hayes, Sacks could be painfully shy, yet effusively gregarious when taken by sudden, ebullient outbursts of boyish enthusiasm.

As a young man wracked with anguish regarding his sexuality and unrequited affections, Sacks once resolved never to live with anyone again. So began 35 years of celibacy, when Sacks took on an almost monastic dedication to his work.

However, Sacks first turned to drugs as a sort of compensation, acquiring a fierce amphetamine habit that proved inspiring and corrosive.

Yet Sacks also sought mastery over his body, becoming an exceptional weightlifter.

Oscillating between roles as Dr Squat the athlete, Wolf the speedfreak biker, and Ollie the kindly but unconventional neurologist, Sacks often remained ill at ease.

Perhaps only in his very late years, through his relationship with Hayes including a very late discovery of French kissing on his 76th birthday did Sacks find comfort.

Read more: Oliver Sacks, the brain and God

Born into a typical, Orthodox Jewish, middle-class family during the 1930s, Sacks father, Sam, was an affable GP, while his mother, Elsie, was a highly regarded gynaecologist, and among the first women surgeons in England.

Sacks reports an an uneasy closeness with his mother.

I think she wanted me to be like her. Sometimes, especially when I was very young she would bring a fetus home, and suggest I dissect it. That was not so easy for a child of ten or eleven.

Later, upon discovering Oliver was gay, his mother declared him an abomination. Though they remained close, Sacks lamented that her words haunted me for much of my life.

Sacks and his brother Michael were sent to boarding school during the Battle of Britain. Soon after this harrowing experience Michael was diagnosed with schizophrenia. Sacks became both terrified of him, terrified for him and retreated into a fondness for chemistry.

Only after many years could Sacks work his way back towards contemplating the minds of others.

Famously clumsy, Sacks initially aspired to be a lab scientist, but after numerous calamities was instructed to Get out, see patients, youll do less harm.

His vocational approach as a neurologist often more resembled a naturalist than a clinician. For Sacks, observation and play trumped diagnosis and prescription.

Indeed, in a biography by Lawrence Weschler, Sacks notes his main neurological tool is the ball You can learn much from how patients play.

Read more: Celebrating Oliver Sacks' romantic science and a life now ending

To compress any life let alone one as Forrest Gumpian as Sacks into a two hour film is something of a fools errand.

Hence, narrative compromises were always likely. Sacks travels in Canada, where he briefly tried joining the Royal Canadian Air Force, are skipped entirely.

Similarly, perhaps in deference to a subject granting privileged access during his last days, the documentary veers ever so slightly into hagiography, framing Sacks as a unifying figure between the clinical and experimental neurosciences.

Still, Sacks influence is undeniably staggering, and His Own Life provides a compelling account of the empathetic labours needed for otherwise lost souls to be storied into the world.

Oliver Sacks: His Own Life is in cinemas now.

Read the original:
Film review: the immoderate adventures of Oliver Sacks - The Conversation AU

Fort Collins, Colorado: Reports Globe has published the latest study on Interventional Neurology Devices Market Report Analysis by Size with Future Outlook, Key Players SWOT Analysis and Forecast to 2026. It uses exploratory techniques such as qualitative and quantitative analysis to identify and present data on the target market. Successful sales strategies have been mentioned that will help you do business in record time and multiply customers.

This report is presented clearly and concisely to help you better understand the structure and dynamics of the market. The trends and recent developments in the Interventional Neurology Devices market were analyzed. The opportunities that lead to the growth of the market were analyzed and presented. Focusing on the global market, the report provides answers to the key questions stakeholders are facing today around the world. Information on market size raises the problem of increasing competitiveness and hampering market-leading sectors and market growth.

Get Exclusive Sample of Report on Interventional Neurology Devices market is available @ https://reportsglobe.com/download-sample/?rid=126683

Some of the Important and Key Players of the Global Interventional Neurology Devices Market:

Interventional Neurology Devices market research report provides detailed information on the following aspects: Industry Size, Market Share, Growth, Segmentation, Manufacturers and Advancement, Key Trends, Market Drivers, Challenges, Standardization, Deployment Models, Opportunities, Strategies, Future Roadmaps and Annual Forecasts to 2027, etc. The report will help you also in understanding the dynamic structure of the Interventional Neurology Devices market by identifying and analyzing market segments. The Global Interventional Neurology Devices 2021 Industry Research Report has given the expected compound annual growth rate (CAGR) as a% of value for a given period of time and clearly helps the user make their decision based on the futuristic chart of the key players on the global Interventional Neurology Devices market. The report introduces some of the major players in the global Interventional Neurology Devices market and offers insightful information about the Interventional Neurology Devices industry such as Business Overview, Interventional Neurology Devices Market Product Segmentation, Revenue Segmentation, and the Latest Information. Developments.

Additionally, the Interventional Neurology Devices market report includes a comprehensive strategic review as well as summarized studies of the growth, key factors, and market opportunity by which to evaluate the Interventional Neurology Devices market and other important market related details on Interventional Neurology Devices. The investigation of the research report also helps uncover accurate industry statistics depicting the ultimate model of the global Interventional Neurology Devices market, including various types, applications, market growth structures, and opportunities. In addition, the study of the market research report provides an investigation and analysis of the past and current performance of the regional market that includes regions by department and subdivision. This regional analysis studies various key market parameters such as Interventional Neurology Devices market growth rate in each region, production volume and capacity, market demand and supply, and return on investment (RoI).

Request a Discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=126683

Some of the key questions answered in the report include-

1. What is the overall structure of the market?2. What was the historical value and what is the forecasted value of the market?3. What are the key product level trends in the market?4. What are the market level trends in the market?5. Which of the market players are leading and what are their key differential strategies to retain their stronghold?6. Which are the most lucrative regions in the market space?

Browse the complete report @ https://reportsglobe.com/product/global-interventional-neurology-devices-market-insight/

Global Interventional Neurology Devices market is segmented based by type, application and region.

Interventional Neurology Devices Market Segmentation, By Type

Interventional Neurology Devices Market Segmentation, By Application

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

Global Interventional Neurology Devicesmarket Key Report Highlights:

This in-depth research documentation offers an illustrative overview of the entire market outlook with details on scope, executive summary, and market segments The report also includes sections on the competitive spectrum, highlighting major players, with a detailed assessment of supply chain management, competition dynamics, and growth objectives. Other crucial details on Porters Five Forces assessment, SWOT analysis, and data triangulation methods have also been included in the report. Other relevant details on production patterns, growth rate, market share of each of the segments have also been pinned in the report. The report also houses crucial analytical details on revenue share and sales projections, besides volumetric estimations of each of the product segments have also been highlighted in the report to encourage unfaltering market decisions and sustainable revenue streams in the global Interventional Neurology Devices market.A dedicated chapter on COVID-19 analysis has therefore been included in this versatile report to encourage future-ready business discretion aligning with post-COVID-19 market environment.

Major Points from Table of Content:

1. Executive Summary2. Assumptions and Acronyms Used3. Research Methodology4. Interventional Neurology Devices Market Overview5. Interventional Neurology Devices Supply Chain Analysis6. Interventional Neurology Devices Pricing Analysis7. Global Interventional Neurology Devices Market Analysis and Forecast by Type8. Global Interventional Neurology Devices Market Analysis and Forecast by Application9. Global Interventional Neurology Devices Market Analysis and Forecast by Sales Channel10. Global Interventional Neurology Devices Market Analysis and Forecast by Region11. North America Interventional Neurology Devices Market Analysis and Forecast12. Latin America Interventional Neurology Devices Market Analysis and Forecast13. Europe Interventional Neurology Devices Market Analysis and Forecast14. Asia Pacific Interventional Neurology Devices Market Analysis and Forecast15. Middle East & Africa Interventional Neurology Devices Market Analysis and Forecast16. Competition Landscape

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://reportsglobe.com/need-customization/?rid=126683

How Reports Globe is different than other Market Research Providers:

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email: [emailprotected]

Web: reportsglobe.com

Read more:
Interventional Neurology Devices Market Size By Analysis, Key Vendors, Regions, Type and Application, and Forecasts to 2027 - NeighborWebSJ

One of Arizonas premier brain injury doctors will travel to Tampa Bay to bring his expertise to the sports worlds biggest stage.

TAMPA, Fla. Dr. Javier Cardenas has worked on the sidelines for three Super Bowls. Hes the director of Concussion and Brain Injury at the Barrow Neurological Institute.

During Sundays game between the Tampa Bay Buccaneers and the Kansas City Chiefs in Florida, Cardenas will serve as a backup concussion doctor.

Cardenas said players are generally cooperative when undergoing concussion protocols, even if it means being pulled from the game.

There is almost never push and pull, Cardenas said. Of course, they want to play, but this process is a collaboration between the NFL and players association.

Concussion protocols were established during negotiations between the players union and the NFL. Over the years, Cardenas says the culture has changed and players understand the dangers of concussions.

When Kansas City Chiefs star quarterback Patrick Mahomes showed signs of concussion in a playoff game three weeks ago, he dutifully exited the field. Cardenas says thats a sign of where the NFL is at today.

Cardenas reminds young athletes that players have even been pulled from the Super Bowl if they show signs of brain injury.

Whether they (high school athletes) say we have a big rivalry game coming up or the state championships, what I remind them is that even in the biggest game of the world, we are removing athletes from play, Cardenas said.

Follow this link:
Valley neurologist will work at Super Bowl for the third time - 12news.com KPNX

Posted: Nov 29, 2020 / 01:55 PM CST / Updated: Nov 29, 2020 / 04:30 PM CST

Dr. Benjamin Segal (left) and Dr. Andrew Sas examine the properties of a newly-discovered cell in a lab at The Ohio State University Wexner Medical Center. This immune cell has the potential to treat neurological conditions long believed to be incurable, including multiple sclerosis, ALS and spinal cord injuries.

COLUMBUS, Ohio (WEHT) For the millions of people suffering from a neurological condition, the devastating effects have long been believed to be irreversible. A discovery at The Ohio State University Wexner Medical Center provides new hope for recovery from degenerative neurological diseases such as ALS and multiple sclerosis as well as from damage caused by traumatic brain and spine injuries and stroke.

The cell discovered by these researchers is a type of white blood cell that not only prevents nerve cell death, but partially reverses nerve fiber damage and promotes nervous system repair. Study findings are published in the journal Nature Immunology.

This immune cell subset secretes growth factors that enhance the survival of nerve cells following traumatic injury to the central nervous system. It stimulates severed nerve fibers to regrow in the central nervous system, which is really unprecedented, said Dr. Benjamin Segal, professor and chair of the Department of Neurology at The Ohio State College of Medicine and co-director of the Ohio State Wexner Medical Centers Neurological Institute.

The next step is to harness this cell and grow it in a lab to enhance its healing effects. Researchers hope these cells can then be injected into patients to improve function and mobility and slow or stop degenerative decline.

For the latest breaking news and stories from across theTri-State, follow Eyewitness News onFacebookandTwitter.

(This story was originally published on November 29, 2020)

LATEST LOCAL NEWS:

See the article here:
Cell discovery may be key to treating currently incurable neurological diseases - Eyewitness News (WEHT/WTVW)

Interventional Neurology Device Market Report offers a comprehensive analysis of the Interventional Neurology Device industry, standing on the readers perspective, delivering detailed market data, and penetrating insights. No matter the client is an industry insider, potential entrant, or investor, the report will provide useful data and information.

The report demonstrates detailed coverage of theInterventional Neurology Device industry and main market trends. The market research includes historical and forecast data, like demand, application details, price trends, and company shares of the leading Interventional Neurology Device by geography, especially focuses on the key regions like United States, European Union, China, and other regions. This report studies and analyzes the in-depth impact of Coronavirus COVID-19 on the Interventional Neurology Device industry.

In addition, the report provides insight into the main drivers of market demand and strategies of suppliers. Key players are profiled, and their market shares in the global Interventional Neurology Device market are discussed. And this report covers the historical situation, present status, and the future prospects of the global Interventional Neurology Device market.

Request for a sample copy of the report to get extensive insights into the Interventional Neurology Device market at https://www.in4research.com/sample-request/57120

Interventional Neurology Device Market: Players Segment Analysis (Company and Product introduction, Interventional Neurology Device Sales Volume, Revenue, Price, and Gross Margin):

Interventional Neurology Device Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share, and Trend 2016-2026):

Interventional Neurology Device Market: Application Segment Analysis (Consumption Volume and Market Share 2016-2026; Downstream Customers and Market Analysis):

Interventional Neurology Device Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue, and Growth Rate 2016-2026):

For more Customization, Connect with us at https://www.in4research.com/customization/57120

Interventional Neurology Device Market Research Objectives:

Any Questions/Queries or need help? Speak with our analyst https://www.in4research.com/speak-to-analyst/57120

Interventional Neurology Device Market Report Includes:

Significance of the report which makes it worth buying:

Buy Full Report athttps://www.in4research.com/buy-now/57120

For More Details Contact Us:

Contact Name: Rohan

Email: [emailprotected]

Phone: +1 (407) 768-2028

https://murphyshockeylaw.net/

Excerpt from:
Interventional Neurology Device Market 2021 Market Exclusive insight on Transformation 2026 Murphy's Hockey Law - Murphy's Hockey Law

Fighting the pandemic will remain a top priority in 2021, not least for the biopharma companies working on the next generation of therapeutics and vaccines against COVID-19. But just because were in a pandemic doesnt mean all other diseases have stopped plaguing humanity. We asked executives which areas might see a resurgence this year, and neurology emerged as a popular horse to bet on.

Part of that interest could be down to Biogens once-failed Alzheimers disease candidate, aducanumab, which is slated for an FDA decision by March 7.

I think neurology will continue to be a big focus, at least in the first half of the year, while aducanumab is out there and all eyes are on the PDUFA, said Shehnaaz Suliman, M.D., president and chief operating officer of Alector, which is working on immuno-neurology approaches to neurodegenerative disease. There was a recent spate of high-priority deals done in the neuro spaceit signals appetite in Big Pharma and Big Biotech to do big value-creating deals.

RELATED: JPM: Alector, Annexon, Athira on what an aducanumab approval could mean for Alzheimer's R&D

Multiple executives agreed that aducanumab would not be a best-in-class drug but that its approval would give the whole field a boost, encouraging interest and investment in neurodegenerative disease R&D. Recent data for a similar drug, Eli Lillys donanemab, also offered hope.

I think its important to continue to go after neurology," said Doug Love, president and CEO of Annexon Biosciences. We are an aging population, and, of course, patients are going to have neurodegenerative disorders We need to think smart and branch out beyond Alzheimers. There are lots of neurodegenerative diseases. There are lots of kinds of dementia we can target.

Its a good time to pursue these indications, Love said, adding, As the field advances with various biomarkers, we will understand earlier in the disease process if drugs are working.

Another reason traditionally big indications like neurology and cardiology are getting more interest is the availability of genetic sequencing and the ability to slice those disease areas up into more manageable segments. It provides a regulatory path for companies working in those areas that previously did not exist, said Rahul Ballal, Ph.D., CEO of Imara, a company working on treatments for sickle cell disease and other blood disorders.

RELATED: JPM: Biogen bullish on Alzheimer's drug approval, sees Lilly data as positive despite AdComm rejection

For a long time, people have run away from those spaces for all the reasons you know: low probability of technical success, large, heterogeneous patient populations, Ballal said. And I think what biotech is doing thats really exciting within the neurodegenerative space and within cardiovascular disease is they are applying a rare disease approach to those diseases by finding patients within the very large swaths.

Whichever areas receive the most interest in 2021, the entire industry should make sure that treatments reach every patient who needs them, said Nessan Bermingham, CEO of Triplet Therapeutics.

We look at whats happening with the (COVID-19) vaccine and whats happening with the rollout of care for individuals who have gotten COVID-19, and the disparities are very clear, Bermingham said. In the U.S. and from a global standpoint, were only going to see those be further emphasized. This is something, as a biotech industry, we need to be very conscious of.

Biopharma companies should think about pricing, distribution and access not just of cutting-edge immuno-oncology meds and gene therapies but also of things like basic care, real-time feedback from doctors, diagnostics and imaging.

As we think about the disparities we face, weve not changed that, and arguably with new therapies coming out, weve actually made those disparities worse, Bermingham added. I think as an industry, we need to go back to the concept of healthcare democracy: that everyone has the right to healthcare.

Go here to see the original:
Beyond COVID-19, where will biopharma focus in 2021? - FierceBiotech

CAMBRIDGE, Mass., Feb. 2, 2021 /PRNewswire/ --Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd. and BioLabs announced today the launch of the Eisai Innovation Center BioLabs, a shared lab and office space for start-ups aiming to innovate in the complex field of neurological diseases. The incubator space is located at the Eisai Center for Genetics Guided Dementia Discovery (G2D2) facility and will become part of BioLabs' national biotechnology network.

"We are excited to announce this collaboration with BioLabs," said Nadeem Sarwar, Ph.D. and President of G2D2. "This specialized incubator will be the first of its kind. With BioLabs' focus on building ecosystems that foster rapid innovation combined with G2D2's state-of-the-art technology to support neurological research, we believe the creation of the Eisai Innovation Center BioLabs will fuel new scientific discoveries and insights. With more than 50 million people globally living with dementia1, there has never been a greater need for the discovery of novel approaches to prevention and treatment."

Housed in the G2D2 facility, the Eisai Innovation Center BioLabs aims to host five to seven neurology-focused start-ups and provide the infrastructure and support to help build their biotech companies. The facility was custom-designed for discovery research, including capabilities for in-vitro biology, molecular and cellular biology including BioSafety Level 2 tissue culture, microscopy, chemical and structural biology and screening. Companies hosted at this incubator will have the opportunity to access the BioLabs network, and interact with the Eisai network, including G2D2 and Eisai's investment arm, Eisai Innovation Inc.

"Launching this incubator space in partnership with BioLabs is an important milestone in our relentless pursuit of a cure for neurological diseases, including Alzheimer's disease, and the fulfillment of our human health care mission. In this new specialized model, we want to advance beyond offering only co-working space," said Vanessa Almendro, MBA, Ph.D. and Head of Strategy and External Innovation at G2D2. "By providing scientific support and enabling potential collaborative opportunities, the Eisai Innovation Center BioLabs is pioneering in providing unique, broad and tailored support to the most prominent biotech companies developing transformative therapies, devices and digital solutions for patients suffering from neurological disorders."

The integration with BioLabs, a national, membership-based network of shared lab and office facilities located in key biotech innovation clusters, empowers companies to rapidly launch their operations in a full-equipped, ready-to-use facility, while collaborating with other innovators in the field.

"The custom-designed space at G2D2 is an ideal home for the Eisai Innovation Center BioLabs. The open-lab layout naturally fosters integration between entrepreneurs, all focused on understanding and advancing the field of neurological diseases. Interacting with a community of peers, specifically within a specialized area of research, sparks collaboration and can significantly fast track a start-up's evolution," said Adam Milne, Chief Operating Officer at BioLabs.

A joint selection committee with members of Eisai Inc., Eisai Innovation Inc. and BioLabs representatives will select the companies to be invited. The selection committee will prioritize start-ups focused on neurology, aligned with Eisai's human health care mission and showing strong potential to develop curative therapeutics. To learn more about the incubator, visit our website.

About Eisai Inc. At Eisai Inc., human health care (hhc)is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.

Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at http://www.eisai.com/US and follow us on Twitter and LinkedIn.

About Eisai Innovation, Inc.Eisai Innovation, Inc.(EII) is a subsidiary of Eisai Inc. It is a strategic investment organization aspiring to identify synergies between the scientific community and the Eisai network of companies. EII contributes toour human health care (hhc)mission by prioritizing disease prevention, prediction and treatment through global investments and research collaboration.

About G2D2Eisai Center for Genetics Guided DementiaDiscovery (G2D2) is the first research center focused on immunodementia. As part of Eisai's Neurology Business Group, G2D2 draws upon Eisai's cutting-edge strengths in human genetics, data sciences and precision chemistry to accelerate discovery of breakthrough immunodementia precision therapeutics.

G2D2 is located in the Alewife Research Center in the Alewife area, in the north-west part of Cambridge, which is one of the world's leading biotechnology clusters where private research organizations in addition to academic institutions such as Harvard University, the Massachusetts Institute of Technology and Tufts University are concentrated. Leveraging the benefits of the location, a research space that can be used by external organizations will be set up at G2D2 to enhance collaboration with outstanding researchers and open innovation initiatives to promote immunodementia drug discovery.

About BioLabsBioLabsis a membership-based network of shared lab facilities located in the nation's key biotech innovation clusters, designed exclusively for high-potential, early-stage life science companies. It offers co-working environments that pair premium, fully equipped and supported lab and space with unparalleled access to capital and industry partners. Find out more athttps://www.biolabs.io/

References

Contact:

Eisai Inc. Libby Holman201-753-1945 [emailprotected]

SOURCE Eisai Inc.

http://www.eisai.com

View post:
Eisai and BioLabs Partner to Create the Eisai Innovation Center BioLabs - PRNewswire